BCL2 and B-cell chronic lymphocytic leukemia: Interestingly, others described a similar upregulation of BCL-2 in CLL cells post CDK inhibitor exposure in vitro (24 hours) and patient treatment (100 mg/m2) with the pan-CDK inhibitor SNS-032 [18, 21].